三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
舒沃替尼单药一线治疗EGFRex20insNSCLCIII期WU-KONG28临床研究方案
舒沃替尼单药一线治疗EGFRex20insNSCLCIII期WU-KONG28临床研究方案
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:291KB
图片尺寸:2268*912
同报告图片
/
4
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
所属报告:
创新药疾病行业专题报告:EGFR ex20ins NSCLC处于突破的前夜布局正当时-231115(57页).pdf
打包全文图表
相关数据
舒沃替尼单药对三代EGFR-TKIs耐药患者显示出疗效信号
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
收藏
行业数据
2023-05-18
原图定位
查看详情
舒沃替尼联合戈利昔替尼显示出优于单药的临床前疗效
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
收藏
行业数据
2023-05-18
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
➢ 舒沃替尼单药一线治疗 EGFR ex20ins NSCLC,针对多种 EGFR exon20ins 突变亚型,均展现出令人鼓舞的疗效和良好的耐受性。舒沃替尼作为小分子靶向治疗,无需与化疗联合治疗,且在给药便利性上也有一定优势,值得期待。2023年 6 月 12 日迪哲发布公告:获欧洲药品监督管理局(EMA)审批意见,获准开展评估舒沃替尼对比含铂化疗一线治疗 EGFR 20 号外显子插入(EGFR Exon20ins)突变型晚期非小细胞肺癌(NSCLC)的全球多中心、随机对照、III 期临床试验(WU-KONG28,NCT05668988),该研究目前正在开展中,包括了中国、美国、欧洲在内多个国家的研究中心参与。WU-KONG28 临床研究方案如下:
行业数据
原图定位
当前图表所属:
创新药疾病行业专题报告:EGFR ex20ins NSCLC处于突破的前夜布局正当时-231115(57页).pdf
EGFRex20insNSCLC一线治疗指南尚无有效疗法推荐
不同突变亚型的EGFRex20ins对不同治疗药物的IC50值
特殊的空间结构致使EGFRex20insNSCLC药物开发难度较大
EGFRPROTAC全球竞争格局
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》